In an interview from #iwCLL2025, Nicolas Martinez-Calle provides insight into the UNCOVER project, which aims to evaluate inequalities in the diagnosis and survival of patients with CLL in England.
Watch here:
👉 buff.ly/FZdouqO 👈
#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
🎥 Vanthana Bharathi of @mdanderson.bsky.social discusses optimizing preventive care for patients with CLL using evidence-based strategies:
👉 buff.ly/BKMPQGT 👈
#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky
The IMPROVE trial compared the impact of paused versus continuous BTKi therapy during vaccination in patients with CLL.🩸💉
We recently had the pleasure of speaking to Helen Parry to find out more about the study:
🎥 buff.ly/j1K0VV8
#CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc
🎥 Mazyar Shadman of @fredhutch.org presents the results of a post hoc analysis & MAIC comparing the outcomes of fit patients treated with zanubrutinib in the SEQUOIA trial to the outcomes of patients treated with AV in AMPLIFY:
👉 buff.ly/paPH5vx 👈
#CLLsm #iwCLL2025 #Leusm #CTSM #BloodSky #HemeSky
It was great to catch up with the wonderful Anna Schuh at #iwCLL2025 to hear about ongoing efforts to improve the outcomes & care of patients with CLL in resource-limited settings.
Watch the interview here:
🎥 buff.ly/sZGLLe2
#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
How should physicians approach the management of patients with CLL who relapse following treatment with a triplet regimen? 💭🩸
Jacob Soumerai discussed this in a recent interview:
🎥 buff.ly/6qCplqB
#CLLsm #Leusm #iwCLL2025 #HemOnc #BloodSky #HemeSky #MedSky
🎥 Moritz Fürstenau comments on the optimal duration of time-limited BTK inhibitor plus BCL2 inhibitor combination therapy in CLL:
👉 buff.ly/BiuqDZd 👈
#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky
At #iwCLL2025, Barbara Eichhorst discussed the efficacy of epcoritamab monotherapy in first-line Richter’s transformation, highlighting 2-year follow-up results from the EPCORE CLL-1 trial.
Watch the interview here:
👉 buff.ly/UvDvXD3 👈
#CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
🎥 Inga Mandac-Smoljanovic outlines the factors that affect the dose of ibrutinib administered in patients with CLL, highlighting the importance of considering comorbidities & concomitant medications when selecting a dose:
👉 buff.ly/Rs2rluB 👈
#iwCLL2025 #CLLsm #Leusm #Leukemia #HemOnc #MedSky
🎥 Marta Coscia shares findings from the BRUIN CLL-321 trial investigating pirtobrutinib versus idelalisib plus rituximab or bendamustine + rituximab in patients with CLL/SLL previously exposed to a covalent BTKi:
👉 buff.ly/rBWUBYh 👈
#iwCLL2025 #CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky
We recently spoke with Krzysztof Jamroziak, who provided valuable insight into the current role of MRD in CLL, highlighting technical aspects and its clinical significance.
Click here to check out the interview:
🎥 buff.ly/20uHc4O
#CLLsm #Leusm #iwCLL2025 #Leukemia #HemOnc #BloodSky #MedSky
Want to hear about the development of rocbrutinib, a 4th-generation BTK inhibitor, as a potential therapeutic option for BTKi-resistant CLL?🩸
Watch our interview with Britten Gordon from #iwCLL2025:
🎥 buff.ly/eKQamE2
#CLLsm #Leusm #Leukemia #HemOnc #MedSky #BloodSky #HemeSky
Want to hear about the safety & efficacy of the CD19-directed CAR-T var-cel (ARI-0001) in patients with CLL or Richter's transformation?💉🩸
Then make sure you watch our interview from #iwCLL2025 with Nil Albiol of @hospitalclinic.bsky.social:
🎥 buff.ly/AnTQebz
#CARTCell #ImmunoOnc #CLLsm #Leusm
Watch our insightful interview from #iwCLL2025, in which Alexey Danilov of @cityofhope.bsky.social discusses the emerging promise of targeted protein degraders in CLL and other heme malignancies:
👉 buff.ly/aDN40ud 👈
#CLLsm #Leusm #Leukemia #HemOnc #MantleCellLymphoma #LYMsm #HemeSky #BloodSky
At #iwCLL2025 last week, we had the pleasure of speaking with Kerry Rogers of @osuhematology.bsky.social to hear about the management of patients with double-refractory CLL.🩸
Watch the interview here:
🎥 buff.ly/ZwOkLWw
#CLLsm #Leusm #Leukemia #HemOnc
We had a fantastic time at #iwCLL2025 last week!🇵🇱
Thank you to the organizers for having us on-site, and to the experts who interviewed with us!😊
Check out our exclusive coverage of the event here, with more coming soon:
👉 buff.ly/Fv2j8p4
#CLLsm #Leusm #Leukemia #HemOnc
It's our first day onsite at #iwCLL2025 and we can't wait for two jam-packed days of expert interviews about all things CLL!🩸
Keep an eye on our site over the coming weeks for our exclusive coverage from the event.🎥
👉VJHemOnc.com
#CLLsm #Leusm #Leukemia #BloodSky #MedSky #HemeSky #HemOnc
